Cargando…

Tranylcypromine Substituted cis-Hydroxycyclobutylnaphthamides as Potent and Selective Dopamine D(3) Receptor Antagonists

[Image: see text] We report a class of potent and selective dopamine D(3) receptor antagonists based upon tranylcypromine. Although tranylcypromine has a low affinity for the rat D(3) receptor (K(i) = 12.8 μM), our efforts have yielded (1R,2S)-11 (CJ-1882), which has K(i) values of 2.7 and 2.8 nM at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jianyong, Levant, Beth, Jiang, Cheng, Keck, Thomas M., Newman, Amy Hauck, Wang, Shaomeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2014
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216217/ https://www.ncbi.nlm.nih.gov/pubmed/24848155 http://dx.doi.org/10.1021/jm401798r

Ejemplares similares

Novel and Potent Dopamine D(2) Receptor Go-Protein Biased Agonists
por: Bonifazi, Alessandro, et al.
Publicado: (2019)

Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis
por: Keck, Thomas M., et al.
Publicado: (2015)

Highly Potent and Selective Dopamine D(4) Receptor Antagonists Potentially Useful for the Treatment of Glioblastoma
por: Pavletić, Pegi, et al.
Publicado: (2022)

USE OF TRANYLCYPROMINE IN SEVERE RESISTANT DEPRESSION : A CASE REPORT
por: Maulik, Pallab K., et al.
Publicado: (1999)

High Affinity Dopamine D(3) Receptor (D(3)R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D(3)R Knockout Mice
por: Boateng, Comfort A., et al.
Publicado: (2015)

Effects of in vitro Amitriptyline, Fluoxetine, Tranylcypromine and Venlafaxine on Saphenous Vein Grafts
por: Akinci, Melek, et al.
Publicado: (2019)

Safety of concomitant tranylcypromine treatment during electroconvulsive therapy (ECT) series
por: Kavakbasi, E., et al.
Publicado: (2022)

Tranylcypromine specificity for monoamine oxidase is limited by promiscuous protein labelling and lysosomal trapping
por: Drechsel, Jonas, et al.
Publicado: (2020)

Heterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity
por: Fioravanti, Rossella, et al.
Publicado: (2022)

Novel spirocyclic tranylcypromine derivatives as lysine-specific demethylase 1 (LSD1) inhibitors
por: Shi, Ying, et al.
Publicado: (2018)

Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells
por: LEE, HYUNG TAE, et al.
Publicado: (2013)

Synthesis and Biological Evaluation of Substituted Desloratadines as Potent Arginine Vasopressin V2 Receptor Antagonists
por: Mu, Shuai, et al.
Publicado: (2014)

Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges
por: Galaj, Ewa, et al.
Publicado: (2020)

Discovery, Optimization, and Characterization of Novel D(2) Dopamine Receptor Selective Antagonists
por: Xiao, Jingbo, et al.
Publicado: (2014)

Serotonin Syndrome Masquerading as Status Epilepticus following Ingestion of Tranylcypromine and Clomipramine and L-Tryptophan: A Case Report
por: Ambarapu, Swetha, et al.
Publicado: (2022)

Behavioral Alterations in Response to Fear-Provoking Stimuli and Tranylcypromine Induced by Perinatal Exposure to Bisphenol A and Nonylphenol in Male Rats
por: Negishi, Takayuki, et al.
Publicado: (2004)

Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study
por: Ludwig, Vera M., et al.
Publicado: (2021)

N-3 (Omega-3) Fatty Acids in Postpartum Depression: Implications for Prevention and Treatment
por: Levant, Beth
Publicado: (2011)

Dopamine receptor alterations in female rats with diet-induced decreased brain docosahexaenoic acid (DHA): interactions with reproductive status
por: Davis, Paul F., et al.
Publicado: (2010)

The selective D3-Receptor antagonist VK4-116 effectively treats behavioral inflexibility in rats caused by self-administration and withdrawal from cocaine
por: Panayi, Marios C., et al.
Publicado: (2023)

Analgesic and anti‐inflammatory properties of novel, selective, and potent EP4 receptor antagonists
por: Chandrasekhar, Srinivasan, et al.
Publicado: (2017)

A Molecular Basis for Selective Antagonist Destabilization of Dopamine D(3) Receptor Quaternary Organization
por: Marsango, Sara, et al.
Publicado: (2017)

Roles of dopamine receptors and their antagonist thioridazine in hepatoma metastasis
por: Lu, Meiling, et al.
Publicado: (2015)

Dopamine receptor antagonists as potential therapeutic agents for ADPKD
por: Paul, Parama, et al.
Publicado: (2019)

Scaffold Hybridization Strategy Leads to the Discovery of Dopamine D(3) Receptor-Selective or Multitarget Bitopic Ligands Potentially Useful for Central Nervous System Disorders
por: Bonifazi, Alessandro, et al.
Publicado: (2021)

Tranylcypromine Causes Neurotoxicity and Represses BHC110/LSD1 in Human-Induced Pluripotent Stem Cell-Derived Cerebral Organoids Model
por: Huang, Jing, et al.
Publicado: (2017)

The MAO Inhibitor Tranylcypromine Alters LPS- and Aβ-Mediated Neuroinflammatory Responses in Wild-type Mice and a Mouse Model of AD
por: Park, HyunHee, et al.
Publicado: (2020)

Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D(2)/D(3) Receptor Agonist Selectivity
por: Zou, Mu-Fa, et al.
Publicado: (2016)

Dopamine D(4) Receptor-Selective Compounds Reveal Structure–Activity Relationships that Engender Agonist Efficacy
por: Keck, Thomas M., et al.
Publicado: (2019)

Development and Characterization of Novel Selective, Non-Basic Dopamine D(2) Receptor Antagonists for the Treatment of Schizophrenia
por: Stępnicki, Piotr, et al.
Publicado: (2023)

Tranylcypromine, a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis
por: Sun, Qunyan, et al.
Publicado: (2016)

A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment
por: Song, Jen-Shin, et al.
Publicado: (2021)

POTENT AND SELECTIVE A2AR MONOCLONAL ANTIBODY ANTAGONIST FOR THE TREATMENT OF CANCER
por: Hu, Changyun, et al.
Publicado: (2023)

Are There Prevalent Sex Differences in Psychostimulant Use Disorder? A Focus on the Potential Therapeutic Efficacy of Atypical Dopamine Uptake Inhibitors
por: Hersey, Melinda, et al.
Publicado: (2023)

Exploring the Effect of Halogenation in a Series of Potent and Selective A(2B) Adenosine Receptor Antagonists
por: Prieto-Díaz, Rubén, et al.
Publicado: (2022)

Diastereoselective Synthesis of Potent Antimalarial Cis-β-lactam Agents
por: Jarrahpour, Aliasghar, et al.
Publicado: (2019)

Catalytically potent and selective clusterzymes for modulation of neuroinflammation through single-atom substitutions
por: Liu, Haile, et al.
Publicado: (2021)

Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D(2)/D(3) Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor
por: Chen, Chunlin, et al.
Publicado: (2021)

Evaluation of Phenol-Substituted Diphyllin Derivatives as Selective Antagonists for Ebola Virus Entry
por: Plescia, Caroline B., et al.
Publicado: (2022)

Effects of dopamine D(4 )receptor antagonist on spontaneous alternation in rats
por: Moustgaard, Anette, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_gjc1co8i623rohc462smar6s6n